PLAGL1 has been reported as a possible epigenetically regulated tumor suppressor gene [127], and NR0B1 (also known as DAX-1) has been repeatedly indicated as a potential target for anticancer therapy in patients with breast cancer [128,129]. This evidence concerns the gene PLAGL1 and breast cancer.